Newsfeeds - Spark Newswire

2 minute read

Earnings

Karyopharm Therapeutics Earnings Perspective: Return On Capital Employed

Today, 10:08 PM

According to Benzinga Pro data, during Q3, Karyopharm Therapeutics (NASDAQ:KPTI) posted sales of $37.69 million. Earnings were up 10.68%, but Karyopharm Therapeutics still reported an overall loss of $43.81 million.

KPTI

4 minute read

54 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

Today, 10:08 PM

Gainers iRhythm Technologies, Inc. (NASDAQ: IRTC) climbed 38.9% to $106.64. iRhythm Technologies commented on the Centers for Medicare and Medicaid Services (CMS) Calendar Year 2022 Medicare Physician Fee Schedule (MPFS) Final Rule.

ACI

25 minute read

Earnings Scheduled For November 3, 2021

By Benzinga Insights

Today, 10:08 PM

Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.

AAWW

2 minute read

Karyopharm Announces Dosing Of First Patient In A Phase 2 Study Investigating Oral Eltanexor In HMA Refractory Myelodysplastic Syndrome

By Benzinga Newsdesk

Today, 10:08 PM

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patient in the Phase 2 expansion of an ongoing open-label Phase

KPTI